Cargando…

The Next Paradigm Shift in the Management of Clear Cell Renal Cancer: Radiogenomics—Definition, Current Advances, and Future Directions

SIMPLE SUMMARY: Radiogenomics is the science of studying imaging–pathology associations on a genomic level. With the potential for improved non-invasive characterization of tumors to predict survival; metastasis; and/or treatment response, it is important for clinicians to have a basic appreciation...

Descripción completa

Detalles Bibliográficos
Autores principales: Gopal, Nikhil, Yazdian Anari, Pouria, Turkbey, Evrim, Jones, Elizabeth C., Malayeri, Ashkan A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833879/
https://www.ncbi.nlm.nih.gov/pubmed/35159060
http://dx.doi.org/10.3390/cancers14030793
_version_ 1784649044922990592
author Gopal, Nikhil
Yazdian Anari, Pouria
Turkbey, Evrim
Jones, Elizabeth C.
Malayeri, Ashkan A.
author_facet Gopal, Nikhil
Yazdian Anari, Pouria
Turkbey, Evrim
Jones, Elizabeth C.
Malayeri, Ashkan A.
author_sort Gopal, Nikhil
collection PubMed
description SIMPLE SUMMARY: Radiogenomics is the science of studying imaging–pathology associations on a genomic level. With the potential for improved non-invasive characterization of tumors to predict survival; metastasis; and/or treatment response, it is important for clinicians to have a basic appreciation of this nascent field. The genetic basis for clear cell kidney cancer is more well-defined than many other malignancies, making it an ideal target for radiogenomic analysis. We first define the field of radiogenomics in diagnostic radiology, demonstrating that image biomarkers can be derived either qualitatively or quantitatively, the latter of which often employs machine learning. We then summarize existing literature establishing relationships between image features and single or multiple gene expression patterns in clear cell renal cell carcinoma. Finally, we outline limitations of the scope and methodology of current radiogenomic studies in ccRCC and propose future directions for this field to progress from an experimental setting into the mainstream clinical workflow. ABSTRACT: With improved molecular characterization of clear cell renal cancer and advances in texture analysis as well as machine learning, diagnostic radiology is primed to enter personalized medicine with radiogenomics: the identification of relationships between tumor image features and underlying genomic expression. By developing surrogate image biomarkers, clinicians can augment their ability to non-invasively characterize a tumor and predict clinically relevant outcomes (i.e., overall survival; metastasis-free survival; or complete/partial response to treatment). It is thus important for clinicians to have a basic understanding of this nascent field, which can be difficult due to the technical complexity of many of the studies. We conducted a review of the existing literature for radiogenomics in clear cell kidney cancer, including original full-text articles until September 2021. We provide a basic description of radiogenomics in diagnostic radiology; summarize existing literature on relationships between image features and gene expression patterns, either computationally or by radiologists; and propose future directions to facilitate integration of this field into the clinical setting.
format Online
Article
Text
id pubmed-8833879
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88338792022-02-12 The Next Paradigm Shift in the Management of Clear Cell Renal Cancer: Radiogenomics—Definition, Current Advances, and Future Directions Gopal, Nikhil Yazdian Anari, Pouria Turkbey, Evrim Jones, Elizabeth C. Malayeri, Ashkan A. Cancers (Basel) Review SIMPLE SUMMARY: Radiogenomics is the science of studying imaging–pathology associations on a genomic level. With the potential for improved non-invasive characterization of tumors to predict survival; metastasis; and/or treatment response, it is important for clinicians to have a basic appreciation of this nascent field. The genetic basis for clear cell kidney cancer is more well-defined than many other malignancies, making it an ideal target for radiogenomic analysis. We first define the field of radiogenomics in diagnostic radiology, demonstrating that image biomarkers can be derived either qualitatively or quantitatively, the latter of which often employs machine learning. We then summarize existing literature establishing relationships between image features and single or multiple gene expression patterns in clear cell renal cell carcinoma. Finally, we outline limitations of the scope and methodology of current radiogenomic studies in ccRCC and propose future directions for this field to progress from an experimental setting into the mainstream clinical workflow. ABSTRACT: With improved molecular characterization of clear cell renal cancer and advances in texture analysis as well as machine learning, diagnostic radiology is primed to enter personalized medicine with radiogenomics: the identification of relationships between tumor image features and underlying genomic expression. By developing surrogate image biomarkers, clinicians can augment their ability to non-invasively characterize a tumor and predict clinically relevant outcomes (i.e., overall survival; metastasis-free survival; or complete/partial response to treatment). It is thus important for clinicians to have a basic understanding of this nascent field, which can be difficult due to the technical complexity of many of the studies. We conducted a review of the existing literature for radiogenomics in clear cell kidney cancer, including original full-text articles until September 2021. We provide a basic description of radiogenomics in diagnostic radiology; summarize existing literature on relationships between image features and gene expression patterns, either computationally or by radiologists; and propose future directions to facilitate integration of this field into the clinical setting. MDPI 2022-02-04 /pmc/articles/PMC8833879/ /pubmed/35159060 http://dx.doi.org/10.3390/cancers14030793 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Gopal, Nikhil
Yazdian Anari, Pouria
Turkbey, Evrim
Jones, Elizabeth C.
Malayeri, Ashkan A.
The Next Paradigm Shift in the Management of Clear Cell Renal Cancer: Radiogenomics—Definition, Current Advances, and Future Directions
title The Next Paradigm Shift in the Management of Clear Cell Renal Cancer: Radiogenomics—Definition, Current Advances, and Future Directions
title_full The Next Paradigm Shift in the Management of Clear Cell Renal Cancer: Radiogenomics—Definition, Current Advances, and Future Directions
title_fullStr The Next Paradigm Shift in the Management of Clear Cell Renal Cancer: Radiogenomics—Definition, Current Advances, and Future Directions
title_full_unstemmed The Next Paradigm Shift in the Management of Clear Cell Renal Cancer: Radiogenomics—Definition, Current Advances, and Future Directions
title_short The Next Paradigm Shift in the Management of Clear Cell Renal Cancer: Radiogenomics—Definition, Current Advances, and Future Directions
title_sort next paradigm shift in the management of clear cell renal cancer: radiogenomics—definition, current advances, and future directions
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833879/
https://www.ncbi.nlm.nih.gov/pubmed/35159060
http://dx.doi.org/10.3390/cancers14030793
work_keys_str_mv AT gopalnikhil thenextparadigmshiftinthemanagementofclearcellrenalcancerradiogenomicsdefinitioncurrentadvancesandfuturedirections
AT yazdiananaripouria thenextparadigmshiftinthemanagementofclearcellrenalcancerradiogenomicsdefinitioncurrentadvancesandfuturedirections
AT turkbeyevrim thenextparadigmshiftinthemanagementofclearcellrenalcancerradiogenomicsdefinitioncurrentadvancesandfuturedirections
AT joneselizabethc thenextparadigmshiftinthemanagementofclearcellrenalcancerradiogenomicsdefinitioncurrentadvancesandfuturedirections
AT malayeriashkana thenextparadigmshiftinthemanagementofclearcellrenalcancerradiogenomicsdefinitioncurrentadvancesandfuturedirections
AT gopalnikhil nextparadigmshiftinthemanagementofclearcellrenalcancerradiogenomicsdefinitioncurrentadvancesandfuturedirections
AT yazdiananaripouria nextparadigmshiftinthemanagementofclearcellrenalcancerradiogenomicsdefinitioncurrentadvancesandfuturedirections
AT turkbeyevrim nextparadigmshiftinthemanagementofclearcellrenalcancerradiogenomicsdefinitioncurrentadvancesandfuturedirections
AT joneselizabethc nextparadigmshiftinthemanagementofclearcellrenalcancerradiogenomicsdefinitioncurrentadvancesandfuturedirections
AT malayeriashkana nextparadigmshiftinthemanagementofclearcellrenalcancerradiogenomicsdefinitioncurrentadvancesandfuturedirections